Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1201934
28 May 2021 09:26AM

MEDICLIN focuses on patient safety and innovative concepts in rehabilitation


DGAP-News: MediClin AG / Key word(s): AGM/EGM
MEDICLIN focuses on patient safety and innovative concepts in rehabilitation

28.05.2021 / 09:26
The issuer is solely responsible for the content of this announcement.


MEDICLIN focuses on patient safety and innovative concepts in rehabilitation

At the Annual General Meeting of MEDICLIN Aktiengesellschaft (MEDICLIN) held on May 26, 2021, Chairman of the Management Board Volker Hippler gave a mixed picture of the situation. After the focus of the health policy and legislative measures aimed at preventing an overload of the health system, MEDICLIN reacted quickly and professionally to the new requirements. "We have fulfilled our responsibility as a health care provider in dealing with the pandemic, even if this left its mark on our earning power in the 2020 financial year", said Volker Hippler, explaining the business development.

Tino Fritz, Chief Financial Officer of MEDICLIN, commented on the current situation as follows in response to a shareholder question: "Of course we are working on getting the occupancy up again, but the sales and earnings development for the year as a whole will depend on the development of the pandemic and the level of protective shielding benefits. These will be much lower for the year 2021."

Overall, the protective shield benefits decided by politicians and the payments from the cost providers, as in the 2020 financial year, only compensate for a small part of the capacity losses and the higher costs.

Patient safety comes first

In his speech, the CEO emphasized that the focus is on the health and thus the safety of patients and employees. The hygiene concepts work well, as do the treatment and therapy concepts under special corona-related requirements. The feedback on patient satisfaction confirms this for the Group.

Competence in post-COVID and long-COVID treatments

He particularly highlighted the interdisciplinary expertise that MEDICLIN has in the treatment of post-COVID and long-COVID patients. Pneumology experts work closely with experts in neurology, cardiology, psychiatry and psychosomatics. MEDICLIN has so far treated successfully more than 1,250 corona patients, and demand has risen sharply.

Innovative concepts in rehabilitation

Dr. York Dhein, Member of the Management Board of MEDICLIN and responsible for this business segment, explained the future requirements of a performance based rehabilitation. "It will be a particular challenge to adapt rehabilitation to the changing demographic and social requirements with innovative performance-based concepts," he said and added: "That we can quickly build up and implement knowledge in our company MEDICLIN has shown in the treatment of post- and long-COVID patients."

Information on the Annual General Meeting

At the Annual General Meeting of MEDICLIN Aktiengesellschaft 91.81% of the share capital was represented.

With a large majority of 96.81%, the Annual General Meeting passed a new remuneration system for the Management Board.

The actions of the Board of Management and the Supervisory Board were approved for 2020 with majorities of 98.57% and 98.41%, respectively.

Because of the pandemic, the event again took place virtually on the Internet to protect the health of all those involved.

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a Company of the Asklepios-Group.



28.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1201934

 
End of News DGAP News Service

1201934  28.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1201934&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.